Portola Pharmaceuticals (PTLA) : Traders are bullish on Portola Pharmaceuticals (PTLA) as it has outperformed the S&P 500 by a wide margin of 22.96% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 9.24%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.82% in the last 1 week, and is up 20.47% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 12.47% and the 50-Day Moving Average is 0.44%.The 200 Day SMA reached 19.46% Portola Pharmaceuticals, Inc. has dropped 2.44% during the last 3-month period . Year-to-Date the stock performance stands at -54.13%.
Portola Pharmaceuticals (PTLA) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $40 and the lowest price target forecast is $28. The average forecast of all the analysts is $34 and the expected standard deviation is $8.49.
For the current week, the company shares have a recommendation consensus of Buy. Portola Pharmaceuticals (NASDAQ:PTLA): The stock opened at $23.29 and touched an intraday high of $24.36 on Friday. During the day, the stock corrected to an intraday low of $23.29, however, the bulls stepped in and pushed the price higher to close in the green at $23.6 with a gain of 2.48% for the day. The total traded volume for the day was 1,609,536. The stock had closed at $23.6 in the previous trading session.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.